25
November 2024
IXICO plc
("IXICO" or the
"Company")
Notice of Results and
Investor Presentation
IXICO PLC (AIM: IXI), the
global medical imaging analysis company delivering insights in
neuroscience, confirms that it will issue its Full Year
Results for the year to 30 September
2024 on Wednesday 4 December 2024.
Bram Goorden (CEO)
and Grant Nash (CFO) will provide a live presentation to
all existing and potential shareholders relating to their Full
Year Results and IXICO's expansion and growth
strategy via:
The
Vox platform on 4 December 2024 at 4.30pm GMT
Questions can be submitted pre-event by sending
them to community@voxmarkets.co.uk up until 9:00am on the day
before the meeting. There will also be an opportunity to ask
questions during the presentation.
Investors can sign up here:
https://streamyard.com/watch/tuGDjEfcp5K4.
The Investor Meet Company platform
on 5 December 2024 at 4:30pm
GMT.
Questions can be submitted pre-event
via your Investor Meet Company dashboard up
until 9:00am the day before the meeting or at any time
during the live presentation.
Investors can sign up
to Investor Meet Company for free and add to
meet IXICO
PLC via:
https://www.investormeetcompany.com/ixico-plc/register-investor
Investors who already
follow IXICO PLC on the Investor Meet
Company platform will automatically be invited.
For
further information please contact:
|
IXICO plc
|
|
|
Bram Goorden, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
+44
(0)20 3763 7499
|
|
|
|
|
Cavendish Capital
Markets Limited (Nominated adviser and sole
broker)
|
+44 (0)20
7220 0500
|
|
Giles Balleny / Dan
Hodkinson (Corporate Finance)
Nigel Birks (Life Sciences
Specialist Sales)
Harriet Ward (Corporate
Broking)
|
|
|
Michael F Johnson
/ Tamar Cranford-Smith (Sales)
|
|
|
|
|
|
|
|
|
About IXICO | Advanced Analytics | Intelligent
Insights.
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and
human health by turning data into clinically meaningful
information, providing valuable new insights in neuroscience by
supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading
advocate of artificial intelligence in medical image
analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More information is available
on www.IXICO.com